Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 309,978 shares of the biopharmaceutical company’s stock after acquiring an additional 23,474 shares during the period. Transcend Capital Advisors LLC owned 0.11% of Amicus Therapeutics worth $4,399,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Amicus Therapeutics by 97.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 3,638 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at $128,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at $134,000. Los Angeles Capital Management LLC purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at $158,000. Finally, O Shaughnessy Asset Management LLC grew its stake in shares of Amicus Therapeutics by 25.3% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 3,082 shares during the period.

Wall Street Analyst Weigh In

FOLD has been the subject of several research reports. JPMorgan Chase & Co. lowered their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, February 29th.

Amicus Therapeutics Stock Up 1.1 %

Amicus Therapeutics stock traded up $0.11 during trading on Friday, reaching $10.28. 1,714,709 shares of the company’s stock were exchanged, compared to its average volume of 2,662,181. The company’s 50-day moving average is $11.95 and its two-hundred day moving average is $11.99. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.52 and a current ratio of 2.88. Amicus Therapeutics, Inc. has a 52-week low of $9.70 and a 52-week high of $14.57. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of -20.16 and a beta of 0.75.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The business had revenue of $115.08 million for the quarter, compared to analysts’ expectations of $115.11 million. On average, analysts predict that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the transaction, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the transaction, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Michael Clark sold 4,427 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $61,978.00. Following the completion of the transaction, the insider now owns 253,664 shares in the company, valued at approximately $3,551,296. The disclosure for this sale can be found here. In the last three months, insiders sold 48,108 shares of company stock valued at $662,605. Company insiders own 2.10% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.